Annual Accounts Receivable
N/A
December 31, 2023
Summary
- BCLI annual accounts receivable is not available.
Performance
BCLI Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly Accounts Receivable
N/A
September 30, 2024
Summary
- BCLI quarterly accounts receivable is not available.
Performance
BCLI Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Accounts Receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
BCLI Accounts Receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | - |
| 3 y3 years | - | - |
| 5 y5 years | - | - |
BCLI Accounts Receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | ||||
| 5 y | 5-year | ||||
| alltime | all time |
Brainstorm Cell Therapeutics Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2019 | - | $1.92 M(+0.4%) |
| Jun 2019 | - | $1.92 M(+141.1%) |
| Mar 2019 | - | $795.00 K(+61.6%) |
| Sep 2018 | - | $492.00 K(-49.0%) |
| Jun 2018 | - | $964.00 K(-13.7%) |
| Mar 2018 | - | $1.12 M(+251.3%) |
| Sep 2017 | - | $318.00 K(-56.7%) |
| Jun 2017 | - | $735.00 K(+263.9%) |
| Mar 2017 | - | $202.00 K(+83.6%) |
| Sep 2016 | - | $110.00 K(-91.3%) |
| Jun 2016 | - | $1.26 M(+161.4%) |
| Mar 2016 | - | $484.00 K(-41.2%) |
| Sep 2015 | - | $823.00 K(+226.6%) |
| Jun 2015 | - | $252.00 K(-63.6%) |
| Mar 2015 | - | $693.00 K(+54.0%) |
| Sep 2014 | - | $450.00 K(-45.8%) |
| Jun 2014 | - | $831.00 K(+4.9%) |
| Mar 2014 | - | $792.00 K(+57.8%) |
| Sep 2013 | - | $502.00 K(-19.0%) |
| Jun 2013 | - | $620.00 K(+0.5%) |
| Mar 2013 | - | $617.00 K(+37.4%) |
| Sep 2012 | - | $449.00 K(+6.7%) |
| Jun 2012 | - | $421.00 K(-12.7%) |
| Mar 2012 | - | $482.00 K(+30.6%) |
| Sep 2011 | - | $369.00 K(-13.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2010 | $427.00 K(+1933.3%) | $427.00 K(+141.2%) |
| Jun 2010 | - | $177.00 K(+12.0%) |
| Mar 2010 | - | $158.00 K(+69.9%) |
| Sep 2009 | - | $93.00 K(+78.8%) |
| Jun 2009 | - | $52.00 K(+20.9%) |
| Mar 2009 | - | $43.00 K(+104.8%) |
| Dec 2008 | $21.00 K(-84.7%) | $21.00 K(-75.9%) |
| Sep 2008 | - | $87.00 K(+27.9%) |
| Jun 2008 | - | $68.00 K(+3.0%) |
| Mar 2008 | - | $66.00 K(-51.8%) |
| Dec 2007 | $137.00 K(+756.3%) | $137.00 K(+82.7%) |
| Sep 2007 | - | $75.00 K(-13.8%) |
| Jun 2007 | - | $87.00 K(+148.6%) |
| Mar 2007 | - | $35.00 K(-44.1%) |
| Dec 2006 | $16.00 K(-64.8%) | - |
| Sep 2006 | - | $62.60 K(-0.5%) |
| Jun 2006 | - | $62.90 K(+38.2%) |
| Mar 2006 | - | $45.50 K(+60.2%) |
| Mar 2006 | $45.50 K(-48.1%) | - |
| Dec 2005 | - | $28.40 K(-39.7%) |
| Sep 2005 | - | $47.10 K(-59.6%) |
| Jun 2005 | - | $116.50 K(+33.0%) |
| Mar 2005 | $87.60 K | $87.60 K(+177.2%) |
| Dec 2004 | - | $31.60 K(+152.8%) |
| Sep 2002 | - | $12.50 K |
FAQ
- What is the all time high annual accounts receivable for Brainstorm Cell Therapeutics?
- What is the all time high quarterly accounts receivable for Brainstorm Cell Therapeutics?
What is the all time high annual accounts receivable for Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics all-time high annual accounts receivable is $427.00 K
What is the all time high quarterly accounts receivable for Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics all-time high quarterly accounts receivable is $1.92 M